Market News & Trends
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab With Commencement of First Patient Dosing
Tiziana Life Sciences, Ltd recently announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing…
Abbott & Medtronic Pest Positioned Manufacturers in US Neurology Market
As US tariff policies evolve in 2025, neurology device manufacturers face rising cost pressures and growing uncertainty over production strategy. However, Abbott and Medtronic are…
BioNTech Announces Strategic Transaction to Acquire CureVac
BioNTech SE and CureVac N.V. recently announced they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares…
Aragen Biomanufacturing Site Completes Qualification With First GMP Batches in July 2025
Aragen recently announced it will commence GMP manufacturing at its biologics manufacturing facility in Bangalore, India, from July 2025. Aragen has successfully completed the facility…
Ethris & Thermo Fisher Parther to Enhance Access to mRNA Technology
Ethris GmbH recently announced a strategic collaboration with Thermo Fisher Scientific to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together…
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds From Prior Equipment Sale
Lifecore Biomedical, Inc. recently announced it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head…
Vaxart Reports Positive Clinical Data Demonstrating its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses Than its First-Generation Technology
Vaxart, Inc. recently reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation…
Nicoya Acquires Applied Photophysics, Expanding Biologics Characterization Capabilities for Faster Time-to-Clinic & Reduced Late-Stage Failures
Nicoya Lifesciences, Inc. recently announced its acquisition of Applied Photophysics, bringing a 50-year history of delivering established analytical methods and reliable instrumentation, which will now…
CN Bio Introduces Cross-Species DILI Services to Enhance In Vitro to In Vivo Extrapolation During Preclinical Drug Development
CN Bio has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research…
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension
Gyre Therapeutics recently announced the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (ETA) receptor…
Adcendo ApS Announces First Patient Dosed in Phase 1/2 ADCElerate1 Trial of ADCE-D01
Adcendo recently announced the first patient has been dosed in the Phase 1/2 ADCElerate1 clinical trial evaluating ADCE-D01 in patients with metastatic and/or unresectable soft…
RenaissThera Achieves Discovery Milestone in its Oral Obesity Drug Program
RenaissThera Private Limited recently announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor,…
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Metsera, Inc. recently announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency,…
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the US is Open for Del-Brax & Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD
Avidity Biosciences, Inc. recently announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral…
Nutriband Announces Patent Issued for its Transdermal Abuse Deterrent Technology
Nutriband Inc. recently announced the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled Abuse and Misuse Deterrent…
OBI Pharma Enters ADC Collaboration With TegMine Therapeutics Utilizing GlycOBI & TegMiner Enabling Technologies
OBI Pharma, Inc. and TegMine Therapeutics, Inc. have entered into an ADC-related Master Services Agreement (MSA). Under the terms of the MSA, OBI grants TegMine…
Tjoapack Continues to Expand its Global Infrastructure With Strategic Investments in Injectable Packaging & Cold Chain Capabilities
Tjoapack, the global or a leading contract packaging organization (CPO) serving the pharmaceutical industry, has announced a significant expansion of its contract packaging and cold…
PCI Pharma Services to Provide Updates on New Manufacturing Facility
PCI Pharma Services will use the BIO International Convention, June 16-19 in Boston, as a platform to introduce its new purpose-built facility for large-scale sterile fill-finish…
AstriVax Therapeutics Initiates Clinical Development of a Hepatitis B Immunotherapy Using Launch-iT Technology
AstriVax Therapeutics NV recently announced the start of clinical development with AVX70371 for chronic hepatitis B virus (HBV) infection. The phase I RUBY study (NCT06989788)…
Conduit Pharmaceuticals Enters Joint Development Agreement With Manoira
Conduit Pharmaceuticals Inc. recently announced it has entered into a joint development agreement with Manoira Corporation. Under the terms of the joint development agreement, Manoira…
